Edgen AI operates independently of, and is not controlled by Aspen Digital Financial Limited.
Trump's Saudi nuclear deal drops nonproliferation safeguards in 30-year pact
Edgen Stock·Jul 23 2026, 06:59Share to
Share to
Copy link
[1] Saudi Nuclear Enrichment Is a Mistake - WSJ (https://www.wsj.com/opinion/saudi-nuclear-enr ...)[2] Trump approves nuclear agreement that may allow Saudi Arabia to enrich uranium, two AP sources say (https://www.nydailynews.com/2026/07/22/trump- ...)[3] Trump agrees nuclear deal with Saudi Arabia (https://www.yahoo.com/news/politics/articles/ ...)[4] Trump Approves Landmark Nuclear Deal With Saudi Arabia in Big Win for Kingdom (https://www.msn.com/en-us/news/world/trump-ap ...)[5] Trump approves landmark U.S.-Saudi nuclear deal (https://www.msn.com/en-us/news/world/trump-ap ...)
Related News
Jul 23 2026, 08:17
BMW recalls 318,495 US vehicles over starter motor fire risk
BMW is recalling 318,495 U.S. vehicles because an engine starter may overheat and cause a fire, the National Highway Traffic Safety Administration said Thursday. "The starter motor can overheat due to mechanical wear, posing a fire risk even when the vehicle is not in use," NHTSA said in its recall notice. The agency urged owners to park outdoors and away from structures until repairs are completed. The recall covers multiple BMW models across recent production years, though the automaker has not yet disclosed the specific model breakdown or the estimated repair cost per vehicle. BMW said it is working on a remedy and will notify affected owners by mail. The company did not disclose how many fire incidents, if any, have been reported in connection with the defect. The recall adds to mounting quality costs for BMW, which faces potential legal liabilities from any fire incidents linked to the defect. The company's stock may face pressure as investors assess the financial impact of repairs, legal exposure and brand reputation damage. The recall follows a similar action by Toyota Motor Corp., which recalled its GR Supra over a related starter motor issue and urged owners not to leave vehicles unattended. BMW's next key event will be its disclosure of repair costs and any related legal claims, which could further weigh on the stock. This article is for informational purposes only and does not constitute investment advice.
Jul 23 2026, 08:13
DigitalOcean stock surges 360% as AI cloud demand accelerates
Small and medium-sized businesses are racing to deploy artificial intelligence software, and DigitalOcean Holdings Inc. is emerging as an unlikely beneficiary. The cloud provider, which has long catered to SMBs overlooked by Amazon Web Services and Microsoft Azure, said its remaining performance obligations hit $800 million at the end of the second quarter — a tenfold increase from a year earlier. "The demand for AI compute from SMBs is off the charts," Yancey Spruill, chief executive officer of DigitalOcean, said in a statement previewing the company's quarterly results on July 7. "We're building AI data centers as fast as we can." DigitalOcean generated $257.9 million in revenue during the first quarter, up 22% from a year earlier, and said second-quarter revenue growth accelerated to 29%. AI customers accounted for $170 million of the company's $1.03 billion in annual run-rate revenue at the end of the first quarter, a 221% jump from the prior year. The company's AI-Native Cloud platform, launched this year, features five layers spanning infrastructure to ready-made large language models from partners including Anthropic. **The AI Infrastructure Buildout** DigitalOcean operates 20 data centers equipped with chips from Nvidia Corp. and Advanced Micro Devices Inc., which SMBs can rent through the AI-Native Cloud platform. The company previously guided for 50% revenue growth in 2027 but told investors it plans to revise that forecast higher when it reports full second-quarter results on Aug. 4. The opportunity is significant because the hyperscalers — Amazon, Microsoft and Alphabet Inc.'s Google — have focused their AI offerings on enterprise customers with the largest budgets. That leaves millions of smaller businesses underserved, a gap DigitalOcean is filling with simplified interfaces and personalized support. **Valuation and Investor Outlook** DigitalOcean shares have gained about 360% over the past 12 months, though they remain 25% below their recent peak. The stock trades at 15.4 times sales, well above its long-term average of 8.5 times since going public in 2021. Based on the company's 2027 revenue guidance, the forward price-to-sales ratio drops to 8.1 — and could fall further if management raises its outlook next month. The Aug. 4 earnings report will be a critical test. If DigitalOcean delivers another acceleration in AI-related revenue and lifts its long-term guidance, the stock's premium valuation may prove justified. If growth disappoints, the shares could face a sharp correction given how much optimism is already priced in. *This article is for informational purposes only and does not constitute investment advice.*
Jul 23 2026, 08:12
Scancell to list on Nasdaq via Neuphoria merger and $89m financing
**Oxford-based Scancell is taking its melanoma immunotherapy to a US audience through an all-share merger with Neuphoria Therapeutics and an $89 million financing package.** Scancell Holdings PLC (AIM:SCLP, OTC:SCNLF) agreed to acquire Neuphoria Therapeutics in an all-share transaction that will give the combined company a dual listing on Nasdaq and London's AIM market. Existing Scancell shareholders will own 85.5% of the enlarged group on a pro forma basis, with Neuphoria holders taking 14.5% through American Depositary Shares and contingent value rights tied to Neuphoria's partnered assets. "The transaction will establish Scancell on Nasdaq and enables access to US investors and the broader US life sciences sector for the capital we need to execute the registrational Phase 3 study for iSCIB1+ in advanced melanoma," Chief Executive Officer Dr Phil L'Huillier said. The financing comprises a $39.1 million private placement from new and existing shareholders, a UK placing expected to raise about $12 million, a retail offer of up to $3 million, and a non-binding term sheet with funds managed by BlackRock for debt financing of up to $25 million. Neuphoria's cash balances will contribute at least $10 million, giving the combined company a pro forma net cash position of approximately $79.1 million. **The iSCIB1+ Data That Made This Possible** The deal's centerpiece is iSCIB1+, an off-the-shelf DNA ImmunoBody designed to train the immune system to attack tumor cells. Data from the Phase 2 SCOPE study showed 77% progression-free survival at 22 months when combined with the checkpoint inhibitors ipilimumab and nivolumab — a result that earned fast-track designation from the US Food and Drug Administration. Further progression-free and overall survival data from the same study are expected within the next 12 months. The financing is structured to carry the global registrational Phase 3 trial through its primary readout in the second half of 2028 and extend the group's cash runway into 2029. For context, the standard of care in advanced melanoma — checkpoint inhibitor combinations — typically shows median progression-free survival of 11.5 months in first-line treatment, per published clinical benchmarks. **What Neuphoria Brings to the Deal** Neuphoria, a Nasdaq-listed biotech focused on neuropsychiatric disorders, saw its lead candidate BNC210 miss primary and secondary endpoints in a Phase 3 PTSD trial in October 2025 and has since halted development in social anxiety disorder. The company had $19.4 million in cash as of March 2026. Scancell does not intend to develop Neuphoria's non-partnered assets beyond maintaining key intellectual property, instead focusing on its own oncology pipeline. Neuphoria Chairman Alan Fisher said the deal lets his shareholders "participate in the future value creation of Scancell's differentiated oncology pipeline, while preserving potential upside from Neuphoria's partnered assets through the CVRs." **The Strategic Logic** For Scancell, the transaction solves a structural problem facing many UK-listed biotechs: limited access to the deep capital pools of US life sciences investors. A Nasdaq listing under the ticker SCLT, alongside its existing AIM quotation, opens the door to institutional investors that typically avoid London's junior market. The 10-for-1 share consolidation planned before closing is designed to align the ADS price with US market expectations. Completion is expected in late Q4 2026, subject to shareholder votes from both companies, Nasdaq and AIM admissions, and SEC review of the Form F-4 registration statement. Both boards have approved the transaction unanimously. Scancell shares trade on AIM with a market capitalization of approximately £140 million. The company's pipeline also includes Modi-1, a Moditope peptide in Phase 2 for head and neck and renal cancers, and GlyMab antibodies licensed to Genmab. The combined entity will have a clearer financial runway than most AIM-listed biotechs, but the Phase 3 readout in 2028 remains the single most important catalyst for valuation. This article is for informational purposes only and does not constitute investment advice.